The FDA has approved Apidra (insulin glulisine [rDNA origin] injection, from sanofi-aventis) for the treatment of type 1 diabetes in children ≥4 years old. This approval was based on a 26-week, open-label trial comparing Apidra to insulin lispro in 572 children and adolescents with type 1 diabetes that showed efficacy and side effects were similar in both groups based on HbA1c, self-monitored glucose values, and reports of hypoglycemia.

Apidra is already indicated for type 1 and type 2 diabetes in adults.

For more information call (800) 981-2491 or visit www.apidra.com.